{"id":70167,"date":"2026-07-17T21:30:38","date_gmt":"2026-07-17T13:30:38","guid":{"rendered":"https:\/\/flcube.com\/?p=70167"},"modified":"2026-07-17T21:30:39","modified_gmt":"2026-07-17T13:30:39","slug":"eli-lilly-to-acquire-ataibeckley-for-3-8-billion-accelerating-psychedelic-therapeutics-development-for-treatment-resistant-depression","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70167","title":{"rendered":"Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced a definitive agreement to acquire <strong>AtaiBeckley<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ATAI:NASDAQ\">NASDAQ: ATAI<\/a>), a leading psychedelic drug development company, for up to <strong>$3.8 billion<\/strong>. The acquisition positions Lilly at the forefront of the rapidly evolving psychedelic therapeutics landscape, following recent federal policy shifts supporting accelerated development of treatments for serious mental illness.<\/p>\n\n\n\n<h2 id=\"h-transaction-details\" class=\"wp-block-heading\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Eli Lilly and Company (NYSE: LLY)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>AtaiBeckley (Nasdaq: ATAI)<\/td><\/tr><tr><td><strong>Base Price<\/strong><\/td><td>$6.75 per share in cash<\/td><\/tr><tr><td><strong>Contingent Value Rights (CVR)<\/strong><\/td><td>Up to $2.50 per share upon milestone achievement<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td>$3.8 billion<\/td><\/tr><tr><td><strong>Milestone Programs<\/strong><\/td><td>BPL-003 and VLS-01 development and regulatory achievements<\/td><\/tr><tr><td><strong>Payment Structure<\/strong><\/td><td>Cash plus CVR tied to clinical and regulatory success<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-ataibeckley-pipeline-overview\" class=\"wp-block-heading\">AtaiBeckley Pipeline Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Stage<\/th><th>Mechanism<\/th><th>Indication<\/th><\/tr><\/thead><tbody><tr><td><strong>BPL-003<\/strong><\/td><td>Clinical-stage<\/td><td>Intranasal 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)<\/td><td>Treatment-resistant depression (TRD)<\/td><\/tr><tr><td><strong>VLS-01<\/strong><\/td><td>Clinical-stage<\/td><td>Next-generation neuroplastogen<\/td><td>Severe mental health conditions<\/td><\/tr><tr><td><strong>Discovery Pipeline<\/strong><\/td><td>Preclinical<\/td><td>Next-generation compounds<\/td><td>Multiple psychiatric indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-regulatory-amp-policy-catalyst\" class=\"wp-block-heading\">Regulatory &amp; Policy Catalyst<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Executive Order:<\/strong> April 2026 &#8220;Accelerating Medical Treatment for Serious Mental Illness&#8221; signed by President Trump<\/li>\n\n\n\n<li><strong>Federal Mandate:<\/strong> Directs agencies to expedite research, review, and approval of psychedelics for severe mental health conditions<\/li>\n\n\n\n<li><strong>Market Impact:<\/strong> Expected increase in research funding, regulatory pathway clarity, and investment in psychedelic therapeutics<\/li>\n\n\n\n<li><strong>Strategic Timing:<\/strong> Lilly&#8217;s acquisition capitalizes on favorable policy environment and growing clinical evidence for rapid-acting neuroplastogens<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-opportunity\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Treatment-Resistant Depression Market:<\/strong> Affects approximately 30% of major depressive disorder patients, representing a $15+ billion addressable market<\/li>\n\n\n\n<li><strong>Therapeutic Differentiation:<\/strong> Rapid-acting neuroplastogens offer potential advantages over traditional antidepressants with weeks-to-months onset<\/li>\n\n\n\n<li><strong>Lilly&#8217;s Mental Health Portfolio:<\/strong> Complements existing neuroscience pipeline including Zyprexa, Cymbalta, and emerging GLP-1 psychiatry candidates<\/li>\n\n\n\n<li><strong>Development Acceleration:<\/strong> Lilly&#8217;s regulatory expertise and clinical trial infrastructure expected to significantly advance AtaiBeckley&#8217;s programs<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-analysis\" class=\"wp-block-heading\">Competitive Landscape Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Psychedelic Therapeutics:<\/strong> Emerging field with companies like Compass Pathways, MindMed, and Usona Institute advancing psilocybin programs<\/li>\n\n\n\n<li><strong>5-MeO-DMT Advantage:<\/strong> BPL-003&#8217;s intranasal delivery and unique mechanism may offer differentiated efficacy and safety profile<\/li>\n\n\n\n<li><strong>Big Pharma Entry:<\/strong> Lilly becomes first major pharmaceutical company to make significant acquisition in psychedelic space<\/li>\n\n\n\n<li><strong>Market Validation:<\/strong> $3.8 billion valuation signals strong confidence in long-term commercial potential of psychedelic therapeutics<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the acquisition, regulatory developments, clinical development timelines, and market opportunities. Actual results may differ due to risks including transaction completion, regulatory approvals, clinical trial outcomes, and competitive dynamics in the biopharmaceutical industry.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire AtaiBeckley (NASDAQ: ATAI),&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4863,199,4864,911],"class_list":["post-70167","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ataibeckley","tag-eli-lilly","tag-nasdaq-atai","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire AtaiBeckley (NASDAQ: ATAI), a leading psychedelic drug development company, for up to $3.8 billion. The acquisition positions Lilly at the forefront of the rapidly evolving psychedelic therapeutics landscape, following recent federal policy shifts supporting accelerated development of treatments for serious mental illness.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70167\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire AtaiBeckley (NASDAQ: ATAI), a leading psychedelic drug development company, for up to $3.8 billion. The acquisition positions Lilly at the forefront of the rapidly evolving psychedelic therapeutics landscape, following recent federal policy shifts supporting accelerated development of treatments for serious mental illness.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70167\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-17T13:30:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-17T13:30:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70167#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70167\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression\",\"datePublished\":\"2026-07-17T13:30:38+00:00\",\"dateModified\":\"2026-07-17T13:30:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70167\"},\"wordCount\":399,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AtaiBeckley\",\"Eli Lilly\",\"NASDAQ: ATAI\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70167#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70167\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70167\",\"name\":\"Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-17T13:30:38+00:00\",\"dateModified\":\"2026-07-17T13:30:39+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire AtaiBeckley (NASDAQ: ATAI), a leading psychedelic drug development company, for up to $3.8 billion. The acquisition positions Lilly at the forefront of the rapidly evolving psychedelic therapeutics landscape, following recent federal policy shifts supporting accelerated development of treatments for serious mental illness.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70167#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70167\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70167#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire AtaiBeckley (NASDAQ: ATAI), a leading psychedelic drug development company, for up to $3.8 billion. The acquisition positions Lilly at the forefront of the rapidly evolving psychedelic therapeutics landscape, following recent federal policy shifts supporting accelerated development of treatments for serious mental illness.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70167","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression","og_description":"Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire AtaiBeckley (NASDAQ: ATAI), a leading psychedelic drug development company, for up to $3.8 billion. The acquisition positions Lilly at the forefront of the rapidly evolving psychedelic therapeutics landscape, following recent federal policy shifts supporting accelerated development of treatments for serious mental illness.","og_url":"https:\/\/flcube.com\/?p=70167","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-17T13:30:38+00:00","article_modified_time":"2026-07-17T13:30:39+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70167#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70167"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression","datePublished":"2026-07-17T13:30:38+00:00","dateModified":"2026-07-17T13:30:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70167"},"wordCount":399,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AtaiBeckley","Eli Lilly","NASDAQ: ATAI","NYSE: LLY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70167#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70167","url":"https:\/\/flcube.com\/?p=70167","name":"Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-17T13:30:38+00:00","dateModified":"2026-07-17T13:30:39+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire AtaiBeckley (NASDAQ: ATAI), a leading psychedelic drug development company, for up to $3.8 billion. The acquisition positions Lilly at the forefront of the rapidly evolving psychedelic therapeutics landscape, following recent federal policy shifts supporting accelerated development of treatments for serious mental illness.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70167#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70167"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70167#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70167"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70167\/revisions"}],"predecessor-version":[{"id":70171,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70167\/revisions\/70171"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}